glp-1 for thyroid receptor agonist use more than 1 year may increase cancer risk GLP-1 Weight Loss Medication and

Because of the unknown potential for serious adverse reactions in the breastfed infant due to the possible accumulation of SNAC, an absorption enhancer for Wegovy tablets, and because there are alternative formulations of semaglutide that do not contain SNAC that can be used during lactation, advise patients that breastfeeding is not recommended during treatment with Wegovy tablets

Importantly, nearly 70% of participants in the semaglutide group lost at least 10% of their body weight, a threshold associated with meaningful improvements in cardiovascular and metabolic health markers

Clinical studies have shown that this higher dose leads to greater weight loss compared to the doses used for diabetes management

Manufacturer Rule: Hospira's labeling is explicit refrigerate after opening, use within 28 days

The same reward biology helps explain addiction, binge eating, obesity, and GLP-1 treatment of SUDs